Trial reportFrontiers in immunology2026
Safety, immunogenicity, and long COVID outcomes following inactivated COVID-19 vaccine boosters in elderly Chinese: a prospective cohort study.
Trial report in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adults aged ≥60 years face elevated risks of severe COVID-19 and long COVID. Although inactivated SARS-CoV-2 vaccines are safe and effective, critical gaps remain regarding optimal booster timing, durability of immune responses, and protection against emerging variants in this vulnerable population. Methods: In this prospective cohort study in Zhejiang Province, China, 450 adults aged ≥60 years were randomized to receive an inactivated SARS-Cov-2 vaccine (CoronaVac or Covilo) under three dosing schedules. Neutralizing antibody titers, SARS-CoV-2-specific IgG, and variant-specific neutralization were evaluated using serum samples collected at multiple timepoints. Safety outcomes included local and systemic adverse reactions and long COVID symptoms. Results: Participants (age: 60-80 years; 50.9% male) with balanced baseline demographics were stratified into six subgroups by vaccine type and schedule (S1/S2/S3; n=75 each; all P>0.05). Adverse reaction incidence was low (0.0%-8.0%), with CoronaVac-S3 recipients experiencing significantly more local reactions than Covilo-S3 recipients (8.0% vs. 0.0%; P = 0.0124). Immunogenicity varied markedly at 1 month post vaccination, with the highest geometric mean titers (GMTs) of neutralizing antibodies in both S3 groups (Covilo: 57.2; CoronaVac: 59.4; P<0.001 vs. respective S1/S2 groups), and CoronaVac-S1 inducing higher GMTs than Covilo-S1 (21.8 vs. 15.4; P = 0.009). At 12 months post vaccination, GMTs remained highest in Covilo-S3 (9.9), while CoronaVac-S2 exceeded Covilo-S2 (8.0 vs. 5.1; P = 0.021). Covilo-S2 and -S3 were superior to their CoronaVac counterparts in inhibition against the wild-type strain and Delta variant at 1 month post vaccination (all P<0.05). Multivariate analysis identified male sex as a protective factor against COVID-19 symptoms, long COVID, and fatigue (odds ratios <0.5 and P<0.05 for all). Conclusions: A third booster of inactivated SARS-CoV-2 vaccine administered within 2-6 months of the second dose is safe and significantly boosts humoral immunity in adults ≥60 years. The three-dose Covilo regimen and a 6-month dosing interval optimized immunogenicity and were associated with the lowest risks of COVID-19 symptoms and long COVID, highlighting the importance of vaccine-specific and interval-adjusted booster strategies for older populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.